PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bayer gears up to take on Gilead in lymphoma with Aliqopa green light

Bayer only won its FDA priority review for lymphoma prospect copanlisib this May, but that was long enough for the agency to make up its mind on the med.
Thursday, regulators said they had green-lighted the product, to be known commercially as Aliqopa, in relapsed follicular lymphoma patients who have received at least two prior treatments. The approval comes based on phase 2 data that showed copanlisib could provoke a response in 58.7% of relapsed or refractory follicular lymphoma patients, completely ridding 14.4% of them of cancer.
The drug, a member of the PI3K class, will go head-to-head with Gilead’s Zydelig, a treatment whose life cycle hasn’t exactly gone according to plan. Last March, serious side effects and multiple deaths among trial participants forced the Big Biotech to nix its studies testing the med in the first-line setting.
It’s still around for relapsed patients, though, and Bayer is hoping it can beat out the $168 million Zydelig generated last year. While Aliqopa is an injectable—potentially less convenient than Zydelig, a tablet—the German drugmaker doesn’t think its new med’s format will be an issue.
“There’s obviously some very positive benefits for this type of administration that counteract the fact that it is given by IV,” Robert LaCaze, Bayer EVP and head of Bayer’s oncology strategic business unit, said in an interview earlier this week, noting that it “allows the physicians to help better monitor the patients.”
The launch, meanwhile, will mark Bayer’s first foray into blood cancer, and it’s prepared accordingly. The company has hired hematology experts to staff its sales force and medical organization, Lacaze said, adding that Bayer wants to roll out Aliqopa “from an ownership standpoint.”
“The types of endpoints that you treat … oftentimes in the hematology space, they’re different than what you see in the solid-tumor space,” he said, and that makes “matching up the right skill set with our field force to the physician and the types of patients that they’re seeing” critical.
Aliqopa will join growth products Stivarga and Xofigo, as well as older blockbuster Nexavar, in Bayer’s cancer portfolio. Stivarga also recently scored an approval, in April securing the FDA’s favor as a therapy for second-line liver cancer.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026